Chardan Capital Initiates Coverage On 4D Molecular Therapeutics with Buy Rating, Announces Price Target of $30
Portfolio Pulse from richadhand@benzinga.com
Chardan Capital analyst Geulah Livshits has initiated coverage on 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy rating and a price target of $30.
July 05, 2023 | 9:43 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
4D Molecular Therapeutics has been given a Buy rating by Chardan Capital, with a price target of $30.
The Buy rating and price target set by Chardan Capital indicates a positive outlook for 4D Molecular Therapeutics. This could potentially attract investors, driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100